Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidative SBRT for Oligo-Residual Advanced EGFR-Mutant NSCLC
NCT07822984Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Sep 2030
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 4 years. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07822984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822984.